Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upamostat for Symptomatic COVID-19
NCT04723537Phase 3Terminated
- Sponsor
- RedHill Biopharma
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of upamostat in coronavirus disease 2019 (COVID-19), sponsored by RedHill Biopharma. Started Feb 2021; status: terminated.
02
Drugs
upamostat
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04723537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723537.